A5008891850- Cutaneous lymphoproliferative disorders research
- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- CAR-T cell therapy research
- Fungal Infections and Studies
- Nail Diseases and Treatments
- Cutaneous Melanoma Detection and Management
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Hematological disorders and diagnostics
- Urticaria and Related Conditions
- Eosinophilic Disorders and Syndromes
- Tumors and Oncological Cases
- Cancer Immunotherapy and Biomarkers
- Toxin Mechanisms and Immunotoxins
- Oral Health Pathology and Treatment
- Mast cells and histamine
- Psoriasis: Treatment and Pathogenesis
- Nonmelanoma Skin Cancer Studies
Johns Hopkins University
2023-2025
Johns Hopkins Medicine
2023-2024
Johns Hopkins Hospital
2023
Summary Identifying aberrant T lymphocytes in peripheral blood is essential for diagnosing Sezary syndrome (SS) and a prognostic indicator mycosis fungoides (MF). Flow cytometry using T‐cell receptor constant beta‐1 chain (TRBC1)‐targeting antibody provides refined approach detecting clonality. We evaluated the performance of TRBC1 assay (TRBC1‐aa) 164 patients, compared to standard flow methods assessing aberrancy, demonstrating 92.3% sensitivity 83.5% specificity. TRBC1‐aa accurately...
A 53-year-old woman with mycosis fungoides presented hyperpigmentation of the oral mucosa. Examination mouth revealed multiple coalescing painless nonpruritic black macules and patches on tongue, roof mouth, buccal What is your diagnosis?
There is a need for updated studies regarding the efficacy of single-agent chemotherapy Black patients with cutaneous T-cell lymphoma. This study evaluates outcomes lymphoma in large and diverse cohort patients. Both gemcitabine pegylated liposomal doxorubicin had promising response rates time to next treatment, including recalcitrant
Department of Dermatology, Johns Hopkins University, Baltimore, MD. Correspondence: Joel Sunshine, MD, 601 N. Caroline Street, MD 21287 (e-mail: [email protected]). The authors declare no conflicts interest.